As our parents age, health care stakeholders should determine how to connect with them…and with us (their caregivers)

By Claudia Douglass, Managing Director, Deloitte Consulting LLP

Leaves

This week’s blog, by Claudia Douglas a Managing Director within the Deloitte US firm, first appeared on the US Center for Health Solutions blog site.1 The blog looks at how health care stakeholders can better connect with patients and carers who are unengaged with technological solutions and the benefits they can provide.

Continue reading

Posted on 06/12/2018 | 0 Comments

My Take: Highlights from the 2018 FT Conference panel discussion on the potential for a successful life sciences economy in the UK

By John Haughey, Deloitte Industry Leader, Life Sciences & Health Care

Regulatory

Earlier this month I had the pleasure of chairing a panel of life science experts at the Global Financial Times Pharmaceutical and Biotechnology conference.1 The conference brought together some of our industry’s leading minds to discuss the commercial conundrums of disease prevention, the transformational impact of advanced gene and cell therapies and the hope and hype of patient-centricity. The discussion topic for my panel was - ‘Big Bang? Industrial Strategy - Creating a Successful Life Sciences Economy’, and was focused on the UK’s Industrial Strategy and in particular the UK’s sector deal for life sciences.2 In this week’s blog I wanted to share some of my key takeaways from our animated and insightful discussion.

Continue reading

Posted on 30/11/2018 | 0 Comments

PFI/PF2 no more – How will the NHS Transform its Estate?

By Claire O’Shaughnessy and James Millar

Deloitte-uk-nhs-transform-its-estate

The NHS is transforming how it delivers its services, but one key aspect to enabling this is the need for significant investment in its Estate. According to Sir Robert Naylor’s report last year, the NHS Estate ranges from world class to poorly utilised and not fit for purpose.1 Moreover, Sir Robert estimated that capital requirements could amount to around £10bn. This investment cannot be delivered through public sector funding alone. However, the Chancellor’s announcement in Budget 2018 that there will be no more Private Finance Initiative (PFI)/Private Finance 2 (PF2) Projects, this cuts off a historically well used option for enabling capital investment in the NHS.2 So what next? There are a myriad of potential solutions, and it will require a combination of traditional and innovative approaches to ensure Estates play their part in the transformation of the NHS.

Continue reading

Posted on 22/11/2018 | 0 Comments

Bright future: A new vision for eye health

By Mark Steedman, PhD. Research Manager, Centre for Health Solutions

Deloitte-uk-bright-future-eye

This week’s blog is the third in our series focusing on eye health, which we developed in support of a global policy report that was launched this week at the World Innovation Summit for Health (WISH). Our first blog in the series focused on glaucoma, while our second examined new treatments for age-related macular degeneration (AMD). This latest blog focuses on the main findings and recommendations of the full report Bright future: A new vision for eye health.

Continue reading

Posted on 16/11/2018 | 0 Comments

A bold future for life sciences regulation: Predictions 2025

By Karen Taylor, Director, Centre for Health Solutions

Deloitte-uk-life-sciences-predictions-2025-banner

Following our 2014 and 2017 Life Science and Health Care Predictions reports, ‘A bold future?’ and ‘The future awakens’, this week we launched our third predictions report, A bold future for Life Sciences Regulation: Predictions 2025. This year’s report presents an unashamedly optimistic view on what Life Sciences regulation might look like in 2025 if both life science companies and regulators were to work more collaboratively, embrace disruptive technologies, and acquire new skills and talent. We argue that this would improve not only the productivity of the regulators and industry but also provide patients with access to the latest medical innovation much sooner. We also imagine through a series of ‘portraits’ how a regulator, company and patient might behave in 2025. This week’s blog provides an overview of the four predictions presented in our future of regulation report and examples of the evidence today that enable us to predict a bold future for life sciences regulation in 2025.

Continue reading

Posted on 08/11/2018 | 0 Comments

The rise of e-mental health: How can digital technology build resilience?

By Dr Francesca Properzi, PhD. Research Manager, Centre for Health Solutions

Deloitte-uk-the-rise-of-e-mental-health

Earlier this year, a team of US scientists connected the brains of three people using an interface made of electroencephalography and magnetic stimulation technologies. The new network enabled the three people to communicate by thinking, exchange ideas and successfully play a collaborative game.1 This ground-breaking experiment is yet one example of many other recent scientific advances where digital technologies are transforming our understanding of the mind. While controversial and somewhat alarming, these developments also present a unique opportunity to protect and support mental health, at a time of unprecedented technological changes.

Continue reading

Posted on 02/11/2018 | 0 Comments

Digital transformation in biopharma: Time for a sea change in strategy

By Mark Steedman, PhD. Research Manager, Centre for Health Solutions

Deloitte-uk-boat-navigators-through-lens

Deloitte recently conducted a survey with the MIT Sloan Management Review to assess the digital maturity of companies across a wide variety of industries.1 Our colleagues in the US Center for Health Solutions analysed the responses from biopharma companies and published them in a separate report - Survey finds biopharma companies lag in digital transformation: It is time for a sea change in strategy.2 Headlining the report is the finding that only 20 per cent of biopharma respondents think their companies are digitally mature, compared to 30 per cent across all industries.3 

Continue reading

Posted on 26/10/2018 | 0 Comments

Insights from our State of the State 2018-19 report: How health sector leaders and citizens view the outlook for NHS and social care services

By Karen Taylor, Director, Centre for Health Solutions

Sots

Last week, my public sector colleagues, together with the think tank Reform, published their seventh annual report The State of the State 2018-19: Government beyond Brexit.1 The report once again brought together Deloitte and Reform to reflect on our most pressing public sector issues. The evidence for the report includes a deep analysis of published data, a citizen survey and exclusive interviews with the people who understand the public sector’s challenges best – the people who run it. As in previous years, the NHS and social care are a central feature of the report, and I have used this week’s blog to highlight the main findings on the ‘State of the NHS and social care’.

Continue reading

Posted on 19/10/2018 | 0 Comments

World Mental Health Day: ‘R U OK’?

By Elizabeth Hampson, Director, Monitor Deloitte

World-health-day

Wednesday 10th October was World Mental Health Day 2018, and coincidentally last week I presented the findings from our work in support of the independent review of mental health and employers by Lord Dennis Stevenson and Paul Farmer ‘Thriving at Work’.1 Our report Mental Health and Wellbeing in Employment: A supporting study for the Independent Review explored the cost of poor mental health and the return on investment for employers from mental health interventions in the workplace, and showcased good practice examples from other countries.2 My presentation, in conjunction with Mind, the mental health charity whose CEO is Paul Farmer, was to senior executives from all Virgin companies at one of the Branson homes in Oxfordshire.

Continue reading

Posted on 11/10/2018 | 0 Comments

Fighting the opioid crisis – a UK perspective

By Matthew Thaxter

Tablets

By now, it is likely that most people have heard about the ongoing opioid crisis in the US, as barely a day goes by without some form of media coverage. Recent stories have also emerged of a significant upward trend in opioid prescriptions in the UK. This blog explores some of the drivers behind the US crisis, and how likely we are to see a similar epidemic here in the UK.

Continue reading

Posted on 05/10/2018 | 0 Comments

Consumers want connected medical devices, but demand for digital experts could put further strain on the talent pool for medtech

By Pedro Arboleda, managing director, Deloitte Consulting LLP

Medical

This week, running from September the 24th to the 26th, our colleagues in the US attended AdvaMed’s annual MedTech Conference. At the conference participants heard about the latest innovations, such as new digital products that incorporate the latest advances in wireless technology and increasingly powerful computing capabilities for generating clinical and economic insights. This week’s blog, by Pedro Arboleda, first appeared on the US Center for health solutions website.1 Below, he discusses his worry that given the rapid advancement in digital technologies the industry might overlook another important change that is occurring in parallel—the ability to attract the specific digital talent needed to deliver on the promise of connected medical devices.

Continue reading

Posted on 28/09/2018 | 0 Comments